biote (BTMD) Resumen de Acciones
biote Corp. desarrolla su actividad en el ámbito de la optimización hormonal. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 5/6 |
| Crecimiento futuro | 0/6 |
| Rendimiento pasado | 2/6 |
| Salud financiera | 2/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
BTMD Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de biote Corp.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$2.10 |
| Máximo en las últimas 52 semanas | US$4.75 |
| Mínimo de 52 semanas | US$1.27 |
| Beta | 1.66 |
| Cambio en 1 mes | 5.53% |
| Variación en 3 meses | 55.56% |
| Cambio de 1 año | -49.28% |
| Variación en 3 años | -67.89% |
| Variación en 5 años | -78.29% |
| Variación desde la OPV | -79.10% |
Noticias y actualizaciones recientes
Actualización de narrativa • Jun 22
BTMD: New Interim Leadership And 2026 Outlook Will Support Earnings Upside
Analysts have trimmed their price target on biote by $1, citing updated assumptions around discount rates and forward P/E, while keeping fair value and long term growth expectations broadly in line with prior views. What's in the News for biote biote reaffirmed full year 2026 earnings guidance, maintaining an outlook for revenue above $190 million.Actualización de narrativa • Jun 05
BTMD: Recall Resolution And Higher Spending Will Support Later Earnings Upside
Narrative Update: Biote Analysts have trimmed their average price targets for Biote by around $1, reflecting recent research that points to mixed signals from Q4 results, a lower FY26 outlook after the voluntary recall and higher investment plans, as well as progress on sales force and platform initiatives that could support improved profitability and a lower future P/E assumption. Analyst Commentary Recent research highlights a mix of optimism and caution around Biote, with analysts adjusting price targets lower in response to Q4 results, updated FY26 guidance and ongoing investment plans.Recent updates
Actualización de narrativa • Jun 22
BTMD: New Interim Leadership And 2026 Outlook Will Support Earnings Upside
Analysts have trimmed their price target on biote by $1, citing updated assumptions around discount rates and forward P/E, while keeping fair value and long term growth expectations broadly in line with prior views. What's in the News for biote biote reaffirmed full year 2026 earnings guidance, maintaining an outlook for revenue above $190 million.Actualización de narrativa • Jun 05
BTMD: Recall Resolution And Higher Spending Will Support Later Earnings Upside
Narrative Update: Biote Analysts have trimmed their average price targets for Biote by around $1, reflecting recent research that points to mixed signals from Q4 results, a lower FY26 outlook after the voluntary recall and higher investment plans, as well as progress on sales force and platform initiatives that could support improved profitability and a lower future P/E assumption. Analyst Commentary Recent research highlights a mix of optimism and caution around Biote, with analysts adjusting price targets lower in response to Q4 results, updated FY26 guidance and ongoing investment plans.
Actualización de narrativa • May 19
BTMD: Recall And Investment Reset Will Support 2026 Revenue Recovery Potential
Analysts have trimmed their average price targets for biote to a lower range, generally cutting expectations by about $1 per share as they factor in the impact of a voluntary recall, higher planned investment and a slower pace of new clinic growth before a potential sales recovery in 2026. Analyst Commentary Across recent research, bullish analysts have adjusted their models to reflect the recall, higher planned spending, and a slower clinic ramp, yet many still see room for value creation if management executes on its plan through 2026.Actualización de narrativa • May 02
BTMD: Recall Disruption And Higher Investment Spend Will Set Up Later Upside
Narrative Update Analysts have trimmed the average price target for biote by about $0.20 as they factor in a lower fair value estimate, a higher assumed future P/E, and recent research pointing to recall related pressures, increased investment plans, and mixed clinic growth trends. Analyst Commentary Recent research updates on biote point to a mixed setup, with analysts weighing near term recall and investment headwinds against execution on sales initiatives and clinic growth potential.Actualización de narrativa • Apr 17
BTMD: Recall Resolution And Clinic Productivity Investments Will Support Future Upside
The average analyst price target on biote has been reduced to about $4 from roughly $6, as analysts factor in lower forecast revenue growth, slimmer projected profit margins, a higher discount rate, and a much higher assumed future P/E multiple following recent guidance updates and the impacts of the product recall. Analyst Commentary Recent Street research reflects a reset in expectations, but it also highlights areas where bullish analysts still see room for value creation if biote executes on its plans and manages the recall process effectively.Actualización de narrativa • Apr 03
BTMD: Affordable Medicines Theme Will Support Upside As Investments Settle
Analysts have trimmed biote's average price target as firms reset expectations to a lower range of $2 to $5, citing the impact of a voluntary recall, higher operating investments, and slower clinic growth, even as they acknowledge progress on sales execution and systems upgrades. Analyst Commentary Recent research highlights a reset in expectations around biote, with lower price targets reflecting near term operational and growth headwinds, alongside recognition of execution progress and investments aimed at future expansion.
Actualización de narrativa • Mar 20
BTMD: Affordable Medicines Theme Will Support Upside As 2026 Plan Advances
Analysts have trimmed the consolidated price target for biote to a range of about $2 to $3. This reflects more cautious assumptions on growth and profitability following guidance tied to the voluntary recall, higher investment, and slower clinic expansion.Actualización de narrativa • Mar 06
BTMD: Affordable Medicines Theme Will Drive Upside Despite Recent Cautious Reassessment
Analysts recently trimmed their 12 month price target on biote to $5 from $6, with the change tied to updated views on discount rates, revenue growth potential, profit margins, and a slightly higher assumed future P/E multiple, while still citing the broader affordable medicines theme as a key part of the thesis heading into 2026. Analyst Commentary Recent Street research has highlighted a more cautious tone around biote, with the 12 month price target trimmed to $5 from $6.Actualización de narrativa • Feb 20
BTMD: Affordable Medicines Theme Will Support Upside Case Despite Lower Street Expectations
Analysts have trimmed their price target on biote to $5 from $6, citing updated assumptions for discount rates, revenue growth, profit margins, and future P/E. They continue to highlight the company’s fit within the broader affordable medicines theme.Actualización de narrativa • Feb 05
BTMD: Affordable Medicines Theme Will Support Upside Potential Despite Lowered Expectations
Narrative update on biote Analysts have trimmed their price target on biote to US$5 from US$6, reflecting updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions, while still highlighting affordable medicines as a supportive theme heading into 2026. Analyst Commentary Recent research reflects a more cautious stance on biote's share price while still pointing to the affordable medicines theme as an important support for the story heading into 2026.Actualización de narrativa • Jan 22
BTMD: Affordable Medicines Theme Will Support Reassessed Outlook Into 2026
Analysts recently trimmed their price target on biote to $5 from $6, citing a mix of updated assumptions on fair value, discount rate, growth, margins, and future P/E expectations as they reassessed the stock within the broader affordable medicines theme heading into 2026. Analyst Commentary Recent Street research on Biote has focused on recalibrating expectations around valuation, execution, and growth, with some Bearish analysts taking a more cautious stance even as the broader affordable medicines theme remains in focus heading into 2026.Actualización de narrativa • Jan 07
BTMD: Affordable Medicines Theme And Buybacks Will Support Upside Potential
Analysts have trimmed their price target on biote to $5 from $6, citing a still supportive view on the affordable medicines theme, even as they fine tune assumptions for revenue growth, margins, and future P/E expectations. Analyst Commentary Even with the trimmed price target, bullish analysts continue to frame biote within the affordable medicines theme, suggesting they still see room for the shares to reflect that positioning over time.Actualización de narrativa • Dec 13
BTMD: Share Repurchases Will Support Future Upside In This Bullish Outlook
Analysts have modestly raised their price target on biote to reflect stronger expected revenue growth and a higher future earnings multiple, partially offset by more conservative margin and discount rate assumptions. What's in the News biote Corp.Seeking Alpha • Sep 10
Restructuring At Biote Will Drive Greater Growth And Profitability
Summary I maintain my Strong Buy rating on biote Corp. due to its promising growth prospects, despite ongoing restructuring and short-term earnings pressure. The company’s vertical integration, digital platform growth, and improved cost controls are driving margin expansion and long-term profitability potential. Restructuring aims to accelerate provider wins, deepen practitioner relationships, and boost financial discipline, though it has led to lower 2025 guidance. Valuation remains attractive with significant upside to intrinsic value, but investors should monitor debt levels, potential dilution, and execution risks. Read the full article on Seeking AlphaArtículo de análisis • Aug 09
Results: biote Corp. Exceeded Expectations And The Consensus Has Updated Its Estimates
One of the biggest stories of last week was how biote Corp. ( NASDAQ:BTMD ) shares plunged 26% in the week since its...Actualización de narrativa • Aug 08
Commercial Reorganization And E-Commerce Expansion Will Drive Mixed Future Prospects
The significant drop in biote’s net profit margin combined with a sharply higher future P/E suggests deteriorating profitability and a less attractive valuation outlook, leading to the consensus analyst price target being revised down from $6.40 to $4.98. What's in the News Biote Corp.Artículo de análisis • Aug 08
Benign Growth For biote Corp. (NASDAQ:BTMD) Underpins Stock's 28% Plummet
NasdaqGM:BTMD 1 Year Share Price vs Fair Value Explore biote's Fair Values from the Community and select yours biote...Artículo de análisis • May 10
biote Corp. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
biote Corp. ( NASDAQ:BTMD ) investors will be delighted, with the company turning in some strong numbers with its...Artículo de análisis • May 09
Market Participants Recognise biote Corp.'s (NASDAQ:BTMD) Earnings
With a price-to-earnings (or "P/E") ratio of 37.3x biote Corp. ( NASDAQ:BTMD ) may be sending very bearish signals at...Artículo de análisis • Dec 02
biote Corp. (NASDAQ:BTMD) Soars 26% But It's A Story Of Risk Vs Reward
biote Corp. ( NASDAQ:BTMD ) shares have had a really impressive month, gaining 26% after a shaky period beforehand...Artículo de análisis • Sep 27
Market Cool On biote Corp.'s (NASDAQ:BTMD) Revenues
You may think that with a price-to-sales (or "P/S") ratio of 0.9x biote Corp. ( NASDAQ:BTMD ) is definitely a stock...
Nueva narrativa • Sep 26
Biote's Innovative Strategies And Expansions Set To Enhance Revenue And Shareholder Value
Expanding the practitioner network and launching BioteRx aim to uniquely position the company in the wellness market, possibly boosting revenue through differentiated service offerings.Seeking Alpha • Sep 27
biote initiated as a buy at Truist on leadership in hormone optimization; sees 138% upside
Truist has initiated biote Corp. (NASDAQ:BTMD) with a buy rating highlighting the company's leadership in providing bioidentical hormone replacement therapy to improve hormonal imbalance. The firm has a $10 price target (~138% upside based on Monday's close). Analyst Gregory Fraser said that the company's platform "provides physicians with effective treatment options as well as a source of income" and added that the model has led to revenue and EBITDA growth. He noted that biote's (BTMD) growth strategy is focused on increasing utlilization of both existing and new partner clinics. Truist conducted a survey of 25 physicians who use biote's (BTMD) bioidentical hormone replacement therapy and found they expect to prescribe more of the company's pellet therapy over the next year. Seeking Alpha's Quant Rating views biote (BTMD) as a strong buy.Seeking Alpha • Sep 07
Biote partners with IMAC Holdings
biote Corp (NASDAQ:BTMD) said it had entered into a partnership with IMAC Holdings, to add the latter's services to its network of outpatient clinics that deliver orthopedic, regenerative, and advanced, non-surgical medical procedures. The Company said it had begun training IMAC medical professionals in the Biote Method for launching the treatments at select IMAC Regeneration Centers in September. "We are excited to add Biote’s services to IMAC clinics, which will be used to implement innovative weight loss and hormone optimization therapy within our current patient population," said Jeff Ervin, IMAC Founder and Chief Executive Officer. IMAC Holdings deliver sports medicine, orthopedic care, and restorative joint and tissue therapies for movement restricting pain and neurodegenerative diseases.Rentabilidad de los accionistas
| BTMD | US Pharmaceuticals | Mercado US | |
|---|---|---|---|
| 7D | -7.5% | 1.2% | -2.5% |
| 1Y | -49.3% | 38.7% | 20.1% |
Rentabilidad vs. Industria: Los resultados de BTMD fueron inferiores a los de la industria US Pharmaceuticals, que obtuvo un rendimiento del 38.7% el año pasado.
Rentabilidad vs. Mercado: BTMD obtuvo unos resultados inferiores a los del mercado US, que fueron del 20.1% el año pasado.
Volatilidad de los precios
| BTMD volatility | |
|---|---|
| BTMD Average Weekly Movement | 10.2% |
| Pharmaceuticals Industry Average Movement | 10.2% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Precio estable de las acciones: BTMD no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de BTMD (10%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2012 | 223 | Bob Peterson | www.biote.com |
biote Corp. desarrolla su actividad en el ámbito de la optimización hormonal. Forma a médicos y enfermeros en la optimización hormonal mediante la terapia de sustitución hormonal bioidéntica en hombres y mujeres con desequilibrios hormonales. La empresa ofrece Biote Method, una plataforma integral para la creación de consultas que proporciona a los médicos certificados por Biote los componentes desarrollados para los médicos en el ámbito de la optimización hormonal, que incluyen la educación, la formación y la certificación Biote Method; un software de gestión de consultas que permite a los médicos certificados por Biote pedir, seguir y gestionar el inventario de productos de optimización hormonal y cumplir otros requisitos administrativos; un software de gestión de inventarios para facilitar los pedidos y el control de inventarios; e información sobre los productos de terapia hormonal sustitutiva disponibles, así como soporte de marketing digital y en el punto de atención.
Resumen de fundamentos de biote Corp.
| Estadísticas fundamentales de BTMD | |
|---|---|
| Capitalización bursátil | US$76.44m |
| Beneficios(TTM) | US$15.60m |
| Ingresos (TTM) | US$188.16m |
4.1x
Ratio precio-beneficio (PE)0.3x
Ratio precio-ventas (PS)¿Está BTMD sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de BTMD | |
|---|---|
| Ingresos | US$188.16m |
| Coste de los ingresos | US$56.23m |
| Beneficio bruto | US$131.93m |
| Otros gastos | US$116.33m |
| Beneficios | US$15.60m |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 0.51 |
| Margen bruto | 70.12% |
| Margen de beneficio neto | 8.29% |
| Ratio deuda/patrimonio | -220.4% |
¿Cómo se ha desempeñado BTMD a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/06/24 17:32 |
| Precio de las acciones al final del día | 2026/06/24 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también contamos con guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
biote Corp. está cubierta por 6 analistas. 5 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Jeffrey Van Sinderen | B. Riley Securities, Inc. |
| Kaumil Gajrawala | Jefferies LLC |
| George Kelly | Roth Capital Partners |